ScholarIQanswers from OpenAlex

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma

PaperCitations, authors & open-access status

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma have?

ScholarIQcitation count

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma has 64 citations in the OpenAlex counts ScholarIQ stores.

When was Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma published?

ScholarIQyear

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma has 2017 year in the ScholarIQ index.

Open the OpenAlex record →

What is the open-access status of Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma?

ScholarIQoa status

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma has diamond oa status in the ScholarIQ index.

Open the OpenAlex record →

What is the DOI of Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma?

ScholarIQdoi

The DOI for Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma is on the source record.

Open the DOI →

What is the PMID of Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma?

ScholarIQpmid

The PMID for Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma is on the source record.

Open the PMID →

What is the OpenAlex record for Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma?

ScholarIQopenalex

The OpenAlex for Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma is on the source record.

Open the OpenAlex →

Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma

How many citations does Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma have?

When was Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma published?

What is the open-access status of Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma?

What is the DOI of Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma?

What is the PMID of Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma?

What is the OpenAlex record for Real-world experience of afatinib as a first-line therapy for advanced <i>EGFR</i> mutation-positive lung adenocarcinoma?

Related on ScholarIQ